State of Wisconsin Investment Board raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 34.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 877,713 shares of the biopharmaceutical company’s stock after buying an additional 226,637 shares during the period. State of Wisconsin Investment Board owned approximately 0.11% of Celgene Corporation worth $109,214,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the stock. Motco increased its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the first quarter worth $118,000. Carroll Financial Associates Inc. boosted its stake in shares of Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares during the last quarter. Oakworth Capital Inc. boosted its stake in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the last quarter. Finally, Reilly Financial Advisors LLC boosted its stake in shares of Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 161 shares during the last quarter. Institutional investors own 78.41% of the company’s stock.
Celgene Corporation (NASDAQ CELG) opened at 130.61 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The company has a market cap of $102.18 billion, a price-to-earnings ratio of 40.45 and a beta of 1.89. The firm has a 50-day moving average price of $134.14 and a 200 day moving average price of $124.30.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.44 EPS. Equities analysts expect that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/13/state-of-wisconsin-investment-board-has-109-21-million-stake-in-celgene-corporation-celg-updated-updated.html.
CELG has been the subject of several recent research reports. Leerink Swann raised Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $94.42 to $150.00 in a research note on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $98.00 price target (up previously from $93.00) on shares of Celgene Corporation in a research note on Wednesday, May 17th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a research note on Monday, June 26th. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and upped their target price for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 target price on Celgene Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $147.00.
In related news, insider Rupert Vessey sold 4,785 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The disclosure for this sale can be found here. Insiders sold a total of 235,255 shares of company stock valued at $31,377,042 over the last 90 days. 0.95% of the stock is currently owned by company insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.